Skip to main content

Table 1 Overview over the transition probabilities

From: Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

  To ... (M: Mezavant cohort; A: Asacol cohort)
From ... 1st line 1st line increased dosage 2nd line Failure/relapse Surgery Post surgery Remission Death
Active UC: 1st line   M: 59.5%
A: 67.4%
     M: 40.5%
A: 32.6%
0.0%**
Active UC: 1st line increased dosage    M: 38.5%
A: 39.0%
    M: 61.5%
A: 60.0%
0.0%**
Active UC: 2nd line     M: 32.0%
A: 32.0%
   M: 68.0%
A: 68.0%
0.0%**
Active UC: Failure/relapse      M: 25.8%
A: 25.8%
  M: 74.2%
A: 74.2%
0.0%**
Surgery       M: 97.9%
A: 97.9%
  M: 2.1%
A: 2.1%
Post surgery       M: 100.0%
A: 100.0%
  0.0%**
Remission M: 6.5%*
A: 9.2%*
      M: 93.5%
A: 90.8%
0.0%**
Death         M: 100.0%
A: 100.0%
  1. * This figure decreases as time spent in remission decreases the risk of active episodes [14, 15]
  2. ** The overall cause mortality data [16] (dependent on the age cohort) is below 0.05% and is therefore displayed in the table as 0.0%.